F. Hoffmann-La Roche & Co. was founded in 1896 in Basel, Switzerland, and remains headquartered there today. In 2009, the Roche Group acquired San Francisco-based biotechnology company, Genentech, becoming the world’s largest biotechnology brand. The Roche Group is also the world’s largest provider of in-vitro diagnostics. Genentech, a member of the Roche Group, retained its brand in the United States of America. The Roche brand family (Roche and Genentech corporate brands) ranks #2, with a brand value of USD $15.479 billion. The Roche Group’s key areas of focus include oncology, neuroscience, infectious diseases, immunology, and ophthalmology.
The Roche brand family exerts a greater than industry average influence in driving choice for healthcare professionals (HCPs), who acknowledge the company’s focus on personalized medicine, facilitated by the Roche Group having pharmaceuticals and diagnostics under one roof. The company is viewed as highly committed to collaboration in research and scientific discovery. The Roche Group’s dedication to science and discovery is seen by HCPs as the engine that drives the company’s standing as an industry thought leader.
A commitment to making a difference in both patient lives and the healthcare ecosystem at large is what distinguishes the Roche brand family. HCPs recognize the Roche Group as a company that looks to engage with a range of stakeholders, such as payers, governments, and policymakers, in an effort to improve patient outcomes.